GLP-1受体激动剂与非酒精性脂肪性肝病

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

非酒精性脂肪肝病在组织学表现上主要是:在无过量饮酒因素,并排除继发性肝损伤所出现的肝内脂肪堆积过多,其发病机制与2型糖尿病的胰岛素抵抗(insulin resistance)有密切联系。胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1),是一种能改善胰岛功能,提高胰岛素敏感性的新型降糖药物。在最近的体内和体外研究中,发现GLP-1可通过增加脂肪酸氧化,改善肝脏的葡萄糖代谢,对非酒精性脂肪肝起到明显的改善作用。鉴于以上因素,本文作者就GLP-1减轻NAFLD的作用机制进行探讨,为NAFLD的临床治疗决策提供相应参考。

Non-alcoholic fatty liver disease （NAFLD）, one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. Its pathogenesis is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 （GLP-1） is an incretin which increases insulin sensitivity and regulates glucose metabolism. The recent studies in vivo and in vitro results showed that GLP-1 could present a novel therapeutic effect against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis and improving hepatic glucose metabolism. In view of above factors, we provided an overview of the role and mechanism of GLP-1 in relieving NAFLD in this report